Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. - Wikidata - wikimedia - TriplyDB

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

http://www.wikidata.org/entity/Q33410831

about

Sui generis: gene therapy and delivery systems for the treatment of glioblastoma Current status of gene therapy for brain tumors.Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy Potentiation of TRAIL killing activity by multimerization through isoleucine zipper hexamerization motif Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.Experiment research on inhibition of glioma with sTRAIL in vitro.Lentiviral transfer of an inducible transgene expressing a soluble form of Gas1 causes glioma cell arrest, apoptosis and inhibits tumor growth.Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine.The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1.TRAIL-secreting mesenchymal stem cells promote apoptosis in heat-shock-treated liver cancer cells and inhibit tumor growth in nude mice.MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.

P2860

Q26850467-7506877B-07F9-4846-A430-C58CF5DD2774 Q34318157-1599B754-A32D-4609-A240-9B6623EF9A95 Q35006015-C51C1C72-5AE7-4758-8ABF-3A0AE7F7E2A0 Q35569426-95A20168-275E-4E5C-8D3B-D3C518A93910 Q37351154-C6FC980C-3D77-4726-ACAC-94401093897F Q37728530-654F9A87-50E7-4640-8A94-B87F7EEDC873 Q38885494-1E270B54-AD89-4EFE-B5AE-FE3E2B870787 Q38888391-A5B5AA6D-36C9-40E5-8994-C0A37C28B3DC Q39071318-8D1379A0-2B23-445D-AE21-FE6EC134D868 Q39649349-AEB293BD-5AF0-4430-98D1-C427A53771DA Q39863924-9CFE1919-9B52-4FE1-9336-0913C232F0FC Q41221061-65063653-42DA-4D6A-8B22-E2A96D4E4D1D Q42241898-CEAACA1A-C3A6-4C32-8AC1-52D341117D97 Q44522644-E6E56DB9-FC41-4E9A-8BA8-70FEB5FBD424 Q47549547-D9CE0F78-4FE8-408A-B682-7B3FCD73B60D

P2860

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

http://www.wikidata.org/entity/Q33410831

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@ast

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@en

type

label

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@ast

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@en

prefLabel

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@ast

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@en

P1433

Q33410831-69B1CD55-CA36-4A98-AB60-CDECAD4654AB

P1476

Q33410831-8C06DF89-8DE8-4BD1-96F7-16F79FD61EBE

P2093

Q33410831-115836A8-2EDC-48D3-B685-FB18507E995C

Q33410831-15C59239-E182-4346-B4F8-5960DF2BDAEE

Q33410831-3AFCCEDE-7123-4BF7-A421-FC40E95DF86F

Q33410831-3C9ADC41-E400-44B3-8DCA-58ED97E8365D

Q33410831-45F7FD78-9160-4024-9860-0EF3290D8AA5

Q33410831-59A30497-D317-4AF9-9522-6F34E6FB9D0D

Q33410831-6312DE8E-16D9-4C40-A4CD-2C2853E1DBEF

Q33410831-9C29263B-0020-42AE-9764-7B68810CD7D0

Q33410831-E1266B1B-8213-4311-BCF4-76228E383050

Q33410831-F22DDFDA-BF48-4CC2-B41C-8CC63A396077

P2860

Q33410831-09A0E0FE-BBD3-42B1-A744-01468A4DAE02

Q33410831-294B3A06-7A3E-4ADD-871D-5ABD0E67D59A

Q33410831-2D0946A8-312E-4AE2-ADC0-E43E6CE1A9CF

Q33410831-4DF47597-E884-4469-8035-15AD574F302C

Q33410831-56946558-3A81-4487-8CF5-D321D617A34D

Q33410831-6B825EC6-2227-4C9A-A27E-994BB37A399D

Q33410831-7054E1A2-BB44-488D-964A-CE329A7F0AE5

Q33410831-76912500-12DF-4184-AB82-DF31FACCC8FA

Q33410831-79BE0987-0DE5-4F3B-BF4F-C36BA96BDC7F

Q33410831-7F39AA86-EAAE-4918-8BCB-D46D6C57729A

P304

Q33410831-AE71F061-0C6E-4403-8917-245F98D51FC2

P31

Q33410831-837A985B-6D3A-48DF-9CBC-4C7B22C5E071

P356

Q33410831-F6A35F61-E624-45BF-9291-0B2AE8A6FD39

P407

Q33410831-F446FF23-5EDE-4C82-8519-5BACD46BACE1

P433

Q33410831-8E68164F-6D92-4C2E-98CD-662C20E204DB

P478

Q33410831-502F25F3-F215-4A8C-A8F2-D19EB2D42975

P577

Q33410831-A80E27D2-75BB-48E9-8050-478488905996

P5875

Q33410831-5D92EA8B-60E2-45CD-81EC-8726A0D62DBC

P698

Q33410831-9EEF5B1F-944F-491E-AB75-6E82BAFEF210

P932

Q33410831-C80E8E24-6141-4018-BA7D-091DC0FAC1DA

P356

JOURNAL.PONE.0004545

P1433

P1476

Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

@en

P2093

Byong-Moon Kim

http://www.w3.org/2001/XMLSchema#string

Chae-Young Kim

http://www.w3.org/2001/XMLSchema#string

Dai-Wu Seol

http://www.w3.org/2001/XMLSchema#string

Kang-Won Song

http://www.w3.org/2001/XMLSchema#string

Moonsup Jeong

http://www.w3.org/2001/XMLSchema#string

Paul D Robbins

http://www.w3.org/2001/XMLSchema#string

Sin-Soo Jeun

http://www.w3.org/2001/XMLSchema#string

Soon-Hye Park

http://www.w3.org/2001/XMLSchema#string

Timothy R Billiar

http://www.w3.org/2001/XMLSchema#string

Yong Ko

http://www.w3.org/2001/XMLSchema#string

P2860

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

The receptor for the cytotoxic ligand TRAIL

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

Identification and characterization of a new member of the TNF family that induces apoptosis

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

Safety and antitumor activity of recombinant soluble Apo2 ligand.

P304

e4545

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0004545

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24027217

http://www.w3.org/2001/XMLSchema#string

P698

19229339

http://www.w3.org/2001/XMLSchema#string

P932

2641005

http://www.w3.org/2001/XMLSchema#string